GEA
BLFS icon

Glen Eagle Advisors’s BioLife Solutions BLFS Stock Holding History

Glen Eagle Advisors’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30
Closed -$1.08K – 1045
2021
Q1 		$1.08K Sell
30
-60
-67% -$2.37K ﹤0.01% 939
2020
Q4 		$3.59K Buy
+90
New +$3.07K ﹤0.01% 781

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Glen Eagle Advisors's BLFS Position: Q2 2021 in Review

Glen Eagle Advisors sold out of BioLife Solutions (BLFS) in Q2 2021, closing a stake of 30 shares — an estimated $1.08K sold.

Glen Eagle Advisors first reported a position in BLFS in Q4 2020 and held it in 2 quarters. The position peaked at $3.59K in Q4 2020. 132 funds tracked by Wall St. Rank hold BLFS as of Q2 2021.

  • Glen Eagle Advisors reported no remaining BioLife Solutions position as of Q2 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 30 BioLife Solutions shares in Q2 2021, an estimated $1.08K.
  • Glen Eagle Advisors first reported a position in BioLife Solutions in Q4 2020 and held it in 2 quarters.
  • Glen Eagle Advisors's BioLife Solutions position peaked at $3.59K in Q4 2020.
  • 132 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2021.

Based on Glen Eagle Advisors's 13F filing for Q2 2021, filed 13 Aug 2024.